Abstract
Objective: To assess the impact of subcutaneous and intravenous interleukin-2 (IL-2) on health-related quality of life (HRQOL) in adults with HIV-1 receiving highly active antiretroviral therapy (HAART). Design: Randomized clinical trial. Setting: Twenty-two institutions from the Adult AIDS Clinical Trials Group. Patients: One hundred forty-eight HIV-infected adults randomized, with baseline HRQOL data. Methods: HAART (indinavir plus 2 nucleoside analogues) for 12 weeks, followed by 72 weeks of continued HAART alone, HAART plus subcutaneous IL-2, or HAART plus intravenous IL-2. Outcome Measures: Scores for 8 dimensions of HRQOL, an unweighted summary score, and a visual analogue health rating score. Results: The IL-2 subcutaneous group had the best mean change in 6 of 8 dimension subscales and in the summary scale at 28 weeks (16 weeks after baseline). At 52 weeks, the IL-2 subcutaneous group had the best mean change in all the subscales and the summary scale. The differences were statistically significant for 3 subscales and the summary scale. Midcycle changes were statistically significantly worse for the subcutaneous IL-2 group for 4 subscales and the summary scale. Conclusions: We found evidence of a short-term but not long-term adverse impact of IL-2 on HRQOL and some evidence of long-term benefit for the subcutaneous group.
Original language | English (US) |
---|---|
Pages (from-to) | 428-433 |
Number of pages | 6 |
Journal | Journal of Acquired Immune Deficiency Syndromes |
Volume | 40 |
Issue number | 4 |
DOIs | |
State | Published - Dec 2005 |
Keywords
- AIDS
- Clinical trial
- HIV
- Health-related quality of life
- Highly active antiretroviral therapy
- Interleukin-2
ASJC Scopus subject areas
- Infectious Diseases
- Pharmacology (medical)